<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00605865</url>
  </required_header>
  <id_info>
    <org_study_id>A0501090</org_study_id>
    <nct_id>NCT00605865</nct_id>
  </id_info>
  <brief_title>Drug Use Investigation of Jzoloft.</brief_title>
  <official_title>Drug Use Investigation of Jzoloft.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this surveillance is to collect information about 1) adverse drug reactions
      not expected from the LPD (unknown adverse drug reactions), 2) the incidence of adverse drug
      reactions in this surveillance, and 3) factors considered to affect the safety and/or
      efficacy of this drug.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All the patients whom an investigator prescribes the first Sertraline hydrochloride should be
      registered consecutively until the number of subjects reaches target number in order to
      extract patients enrolled into the investigation at random.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants of Treatment Related Adverse Events (TRAEs)</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>All observed or volunteered adverse events and the investigator's opinion of the causal relationship to the study treatment were reported. Definition of an adverse event (AE) is any adverse change in health or side effect that occurs in participates. Treatment related Adverse Events were evaluated in company with the causal relationship to the investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Related Adverse Events (TRAEs) Not Expected From Japanese Package Insert</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Complications</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without complications is significant risk factor, Complications is the patient's current experiences with illnesses, operations, injuries and treatments. The physician of this survey made the diagnosis. (e.g. hypertension, diabetes, etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Concomitant Drug</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without concomitant drug is significant risk factor, Concomitant drugs is the drugs which participant had taken during the observation period of this study to treat for participant's illnesses, injuries etc. The physician of this survey listed all of concomitant drugs. (e.g. paroxetine, milnacipran, etc.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Renal Dysfunction</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without renal dysfunction is significant risk factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Past Medical History of Other Illness</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without Past Medical History of Other Illness is significant risk factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Average Daily Dose</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether average daily dose is significant risk factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Suicidal Ideation (Including Suicide Attempt)</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without suicidal ideation (including suicide attempt) is significant risk factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: 15 Years and Higher of Age or Not</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether 15 years and higher of age or not is significant risk factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors Considered to Affect the Efficacy of Sertraline: Target Disease Severity</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with responders of Sertraline to determine whether target disease severity is significant factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors Considered to Affect the Efficacy of Sertraline: History of Treatment Prior to Administration of Sertraline Hydrochloride</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with responders of Sertraline to determine whether with or without history of treatment prior to administration of Sertraline hydrochloride is significant factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors Considered to Affect the Efficacy of Sertraline: Outpatient/Inpatient</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with responders of Sertraline to determine whether outpatient or inpatient is significant factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors Considered to Affect the Efficacy of Sertraline: Complication ;Complications is the Patient's Current Experiences With Illnesses, Operations, Injuries and Treatments.</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with responders of Sertraline to determine whether with or without complication is significant factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors Considered to Affect the Efficacy of Sertraline: 15 Years and Higher of Age or Not</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with responders of Sertraline to determine whether 15 years and higher of age or not is significant factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors Considered to Affect the Efficacy of Sertraline: Age</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with responders of Sertraline to determine whether age is significant factor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Factors Considered to Affect the Efficacy of Sertraline: Suicidal Ideation (Including Suicide Attempt)</measure>
    <time_frame>Baseline up to 16 weeks</time_frame>
    <description>Number of participants with responders of Sertraline to determine whether with or without suicidal ideation (including suicide attempt) is significant factor</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">2272</enrollment>
  <condition>Panic Disorder</condition>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Sertraline hydrochloride.</arm_group_label>
    <description>Patients taking Sertraline hydrochloride.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sertraline hydrochloride</intervention_name>
    <description>J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.
Dosage, Frequency: According to Japanese LPD, &quot;The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms&quot;.
Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration.</description>
    <arm_group_label>Sertraline hydrochloride.</arm_group_label>
    <other_name>J Zoloft, Zoloft</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The patients to whom an investigator involved in A0501090 prescribes sertraline
        hydrochloride.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients need to be taking Sertraline hydrochloride in order to be enrolled in the
        surveillance.

        Exclusion Criteria:

        Patients not taking Sertraline hydrochloride.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0501090&amp;StudyName=Drug%20Use%20Investigation%20of%20Jzoloft.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2008</study_first_submitted>
  <study_first_submitted_qc>January 30, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2008</study_first_posted>
  <results_first_submitted>August 28, 2012</results_first_submitted>
  <results_first_submitted_qc>August 28, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 1, 2012</results_first_posted>
  <last_update_submitted>August 28, 2012</last_update_submitted>
  <last_update_submitted_qc>August 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Panic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sertraline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Sertraline</title>
          <description>Participants taking Sertraline according to Japanese Package Insert</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2272"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2157"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="115"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sertraline</title>
          <description>Participants taking Sertraline according to Japanese Package Insert</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2157"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Target Disease</title>
          <description>The target disease which was diagnosed by investigator</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Depression/Depressed State</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1870"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Panic Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Depression/Depressed state and Panic Disorder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other than Those Above</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Target Disease Severity</title>
          <description>The severity of target disease which was diagnosed by investigator</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="568"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1423"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Complications</title>
          <description>Complications is the patient's current experiences with illnesses, operations, injuries and treatments. The physician of this survey made the diagnosis. (e.g. hypertension, diabetes, etc.)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="777"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1380"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Concomitant Drug</title>
          <description>Concomitant drugs is the drugs which participant had taken during the observation period of this study to treat for participant's illnesses, injuries etc. The physician of this survey listed all of concomitant drugs. (e.g. paroxetine, milnacipran, etc.)</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Present</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1874"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Absent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Starting Dose</title>
          <description>Starting dose of each participant enrolled in this study</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>25 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="523"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 mg</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other than Those Above</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants of Treatment Related Adverse Events (TRAEs)</title>
        <description>All observed or volunteered adverse events and the investigator’s opinion of the causal relationship to the study treatment were reported. Definition of an adverse event (AE) is any adverse change in health or side effect that occurs in participates. Treatment related Adverse Events were evaluated in company with the causal relationship to the investigational product.</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>Safety analysis population included all enrolled participants who had received at least 1 confirmed administration of Sertraline.</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Participants who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants of Treatment Related Adverse Events (TRAEs)</title>
          <description>All observed or volunteered adverse events and the investigator’s opinion of the causal relationship to the study treatment were reported. Definition of an adverse event (AE) is any adverse change in health or side effect that occurs in participates. Treatment related Adverse Events were evaluated in company with the causal relationship to the investigational product.</description>
          <population>Safety analysis population included all enrolled participants who had received at least 1 confirmed administration of Sertraline.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Treatment Related Adverse Events (TRAEs) Not Expected From Japanese Package Insert</title>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sertraline</title>
            <description>Participants who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Treatment Related Adverse Events (TRAEs) Not Expected From Japanese Package Insert</title>
          <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2157"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dyspnoea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sedation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erectile dysfunction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Complications</title>
        <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without complications is significant risk factor, Complications is the patient's current experiences with illnesses, operations, injuries and treatments. The physician of this survey made the diagnosis. (e.g. hypertension, diabetes, etc.)</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>With Complications</title>
            <description>Participants with complications who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>Without Complications</title>
            <description>Participants without complications who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Complications</title>
          <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without complications is significant risk factor, Complications is the patient's current experiences with illnesses, operations, injuries and treatments. The physician of this survey made the diagnosis. (e.g. hypertension, diabetes, etc.)</description>
          <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="777"/>
                <count group_id="O2" value="1380"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129"/>
                    <measurement group_id="O2" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;complications&quot;. The null hypothesis is there is no difference between &quot;with and without complications&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Concomitant Drug</title>
        <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without concomitant drug is significant risk factor, Concomitant drugs is the drugs which participant had taken during the observation period of this study to treat for participant's illnesses, injuries etc. The physician of this survey listed all of concomitant drugs. (e.g. paroxetine, milnacipran, etc.)</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>With Concomitant Drug</title>
            <description>Participants with concomitant drug who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>Without Concomitant Drug</title>
            <description>Participants without concomitant drug who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Concomitant Drug</title>
          <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without concomitant drug is significant risk factor, Concomitant drugs is the drugs which participant had taken during the observation period of this study to treat for participant's illnesses, injuries etc. The physician of this survey listed all of concomitant drugs. (e.g. paroxetine, milnacipran, etc.)</description>
          <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1864"/>
                <count group_id="O2" value="293"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;concomitant drug&quot;. The null hypothesis is there is no difference between &quot;with and without concomitant drug&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Renal Dysfunction</title>
        <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without renal dysfunction is significant risk factor</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>With Renal Dysfunction</title>
            <description>Participants with renal dysfunction who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>Without Renal Dysfunction</title>
            <description>Participants without renal dysfunction who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Renal Dysfunction</title>
          <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without renal dysfunction is significant risk factor</description>
          <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="2133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;renal dysfunction&quot;. The null hypothesis is there is no difference between &quot;with and without renal dysfunction&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.011</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Past Medical History of Other Illness</title>
        <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without Past Medical History of Other Illness is significant risk factor</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>With Past Medical History of Other Illness</title>
            <description>Participants with past medical history of other illness who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>Without Past Medical History of Other Illness</title>
            <description>Participants without past medical history of other illness who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Past Medical History of Other Illness</title>
          <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without Past Medical History of Other Illness is significant risk factor</description>
          <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="349"/>
                <count group_id="O2" value="1808"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;past medical history of other illness&quot;. The null hypothesis is there is no difference between &quot;with and without past medical history of other illness&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Average Daily Dose</title>
        <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether average daily dose is significant risk factor</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>&lt;25mg</title>
            <description>Participants who took less than 25mg of Sertraline a day on average according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>&gt;=25mg, &lt;50mg</title>
            <description>Participants who took more than 25mg and less than 50mg of Sertraline a day on average according to Japanese Package Insert</description>
          </group>
          <group group_id="O3">
            <title>&gt;=50mg, &lt;75mg</title>
            <description>Participants who took more than 50mg and less than 75mg of Sertraline a day on average according to Japanese Package Insert</description>
          </group>
          <group group_id="O4">
            <title>&gt;=75mg, &lt;100mg</title>
            <description>Participants who took more than 75mg and less than 100mg of Sertraline a day on average according to Japanese Package Insert</description>
          </group>
          <group group_id="O5">
            <title>&gt;=100mg</title>
            <description>Participants who took more than 100mg of Sertraline a day on average according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Average Daily Dose</title>
          <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether average daily dose is significant risk factor</description>
          <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="1049"/>
                <count group_id="O3" value="590"/>
                <count group_id="O4" value="455"/>
                <count group_id="O5" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="175"/>
                    <measurement group_id="O3" value="61"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;average daily dose&quot;. The null hypothesis is there is no difference of five types of average daily dose in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Suicidal Ideation (Including Suicide Attempt)</title>
        <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without suicidal ideation (including suicide attempt) is significant risk factor</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>With Suicidal Ideation (Including Suicide Attempt)</title>
            <description>Participants with suicidal ideation (including suicide attempt) who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>Without Suicidal Ideation (Including Suicide Attempt)</title>
            <description>Participants without suicidal ideation (including suicide attempt) who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: Suicidal Ideation (Including Suicide Attempt)</title>
          <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether with or without suicidal ideation (including suicide attempt) is significant risk factor</description>
          <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="469"/>
                <count group_id="O2" value="1608"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;suicidal ideation (including suicide attempt)&quot;. The null hypothesis is there is no difference between &quot;with and without suicidal ideation(including suicide attempt)&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.014</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: 15 Years and Higher of Age or Not</title>
        <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether 15 years and higher of age or not is significant risk factor</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
        <group_list>
          <group group_id="O1">
            <title>15 Years and Higher</title>
            <description>Participants 15 years and higher of age who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>Under 15 Years</title>
            <description>Participants under 15 years of age who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Risk Factors for Incidence Rate of Treatment Related Adverse Events (TRAEs) of Sertraline: 15 Years and Higher of Age or Not</title>
          <description>Number of participants with Treatment Related Adverse Events (TRAEs) of Sertraline to determine whether 15 years and higher of age or not is significant risk factor</description>
          <population>The safety analysis population consists of the cases that satisfy the participant's conditions and in whom administration of Sertraline was confirmed.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2153"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="261"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The risk factor tested was &quot;15 years and higher of age or not&quot;. The null hypothesis is there is no difference between &quot;15 years and higher of age or not&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.021</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Factors Considered to Affect the Efficacy of Sertraline: Target Disease Severity</title>
        <description>Number of participants with responders of Sertraline to determine whether target disease severity is significant factor</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
        <group_list>
          <group group_id="O1">
            <title>Mild</title>
            <description>Participants whose target disease are mild and who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>Moderate</title>
            <description>Participants whose target disease are moderate and who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O3">
            <title>Severe</title>
            <description>Participants whose target disease are severe and who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Efficacy of Sertraline: Target Disease Severity</title>
          <description>Number of participants with responders of Sertraline to determine whether target disease severity is significant factor</description>
          <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="478"/>
                <count group_id="O2" value="1160"/>
                <count group_id="O3" value="127"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="416"/>
                    <measurement group_id="O2" value="1000"/>
                    <measurement group_id="O3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The factor tested was &quot;target disease severity&quot;. The null hypothesis is there is no difference between &quot;three grade of target disease severity&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Factors Considered to Affect the Efficacy of Sertraline: History of Treatment Prior to Administration of Sertraline Hydrochloride</title>
        <description>Number of participants with responders of Sertraline to determine whether with or without history of treatment prior to administration of Sertraline hydrochloride is significant factor</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
        <group_list>
          <group group_id="O1">
            <title>With History of Treatment Prior to Sertraline</title>
            <description>Participants with history of treatment prior to administration of Sertraline who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>Without History of Treatment Prior to Sertraline</title>
            <description>Participants without history of treatment prior to administration of Sertraline who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Efficacy of Sertraline: History of Treatment Prior to Administration of Sertraline Hydrochloride</title>
          <description>Number of participants with responders of Sertraline to determine whether with or without history of treatment prior to administration of Sertraline hydrochloride is significant factor</description>
          <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="489"/>
                <count group_id="O2" value="1202"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="398"/>
                    <measurement group_id="O2" value="1046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The factor tested was &quot;history of treatment prior to Sertralin&quot;. The null hypothesis is there is no difference between &quot;with and without history of treatment prior to Sertralin&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.003</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Factors Considered to Affect the Efficacy of Sertraline: Outpatient/Inpatient</title>
        <description>Number of participants with responders of Sertraline to determine whether outpatient or inpatient is significant factor</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
        <group_list>
          <group group_id="O1">
            <title>Inpatient</title>
            <description>Participants as inpatients who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>Outpatient</title>
            <description>Participants as outpatients who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Efficacy of Sertraline: Outpatient/Inpatient</title>
          <description>Number of participants with responders of Sertraline to determine whether outpatient or inpatient is significant factor</description>
          <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="1638"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="1410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The factor tested was &quot;outpatient or inpatient&quot;. The null hypothesis is there is no difference between &quot;outpatient or inpatient&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.012</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Factors Considered to Affect the Efficacy of Sertraline: Complication ;Complications is the Patient's Current Experiences With Illnesses, Operations, Injuries and Treatments.</title>
        <description>Number of participants with responders of Sertraline to determine whether with or without complication is significant factor</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
        <group_list>
          <group group_id="O1">
            <title>With Complications</title>
            <description>Participants with complications who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>Without Complications</title>
            <description>Participants without complications who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Efficacy of Sertraline: Complication ;Complications is the Patient's Current Experiences With Illnesses, Operations, Injuries and Treatments.</title>
          <description>Number of participants with responders of Sertraline to determine whether with or without complication is significant factor</description>
          <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="637"/>
                <count group_id="O2" value="1128"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="528"/>
                    <measurement group_id="O2" value="981"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The factor tested was &quot;complications&quot;. The null hypothesis is there is no difference between &quot;with or without complications&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.019</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Factors Considered to Affect the Efficacy of Sertraline: 15 Years and Higher of Age or Not</title>
        <description>Number of participants with responders of Sertraline to determine whether 15 years and higher of age or not is significant factor</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
        <group_list>
          <group group_id="O1">
            <title>15 Years and Higher</title>
            <description>Participants 15 years and higher of age who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>Under 15 Years</title>
            <description>Participants under 15 years of age who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Efficacy of Sertraline: 15 Years and Higher of Age or Not</title>
          <description>Number of participants with responders of Sertraline to determine whether 15 years and higher of age or not is significant factor</description>
          <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1762"/>
                <count group_id="O2" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1508"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The factor tested was &quot;15 years and higher of age or not&quot;. The null hypothesis is there is no difference between &quot;15 years and higher of age or not&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.010</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Factors Considered to Affect the Efficacy of Sertraline: Age</title>
        <description>Number of participants with responders of Sertraline to determine whether age is significant factor</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
        <group_list>
          <group group_id="O1">
            <title>Under 18 Years of Age</title>
            <description>Participants under 18 years of age who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>18-44 Years of Age</title>
            <description>Participants from 18 to 44 years of age who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O3">
            <title>45-64 Years of Age</title>
            <description>Participants from 45 to 64 years of age who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O4">
            <title>Over 65 Years of Age</title>
            <description>Participants over 65 years of age who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Efficacy of Sertraline: Age</title>
          <description>Number of participants with responders of Sertraline to determine whether age is significant factor</description>
          <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="955"/>
                <count group_id="O3" value="487"/>
                <count group_id="O4" value="289"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="829"/>
                    <measurement group_id="O3" value="412"/>
                    <measurement group_id="O4" value="245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The factor tested was &quot;age&quot;. The null hypothesis is there is no difference between &quot;four groups of age&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Factors Considered to Affect the Efficacy of Sertraline: Suicidal Ideation (Including Suicide Attempt)</title>
        <description>Number of participants with responders of Sertraline to determine whether with or without suicidal ideation (including suicide attempt) is significant factor</description>
        <time_frame>Baseline up to 16 weeks</time_frame>
        <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
        <group_list>
          <group group_id="O1">
            <title>With Suicidal Ideation (Including Suicide Attempt)</title>
            <description>Participants with suicidal ideation (including suicide attempt) who took Sertraline according to Japanese Package Insert</description>
          </group>
          <group group_id="O2">
            <title>Without Suicidal Ideation (Including Suicide Attempt)</title>
            <description>Participants without suicidal ideation (including suicide attempt) who took Sertraline according to Japanese Package Insert</description>
          </group>
        </group_list>
        <measure>
          <title>Factors Considered to Affect the Efficacy of Sertraline: Suicidal Ideation (Including Suicide Attempt)</title>
          <description>Number of participants with responders of Sertraline to determine whether with or without suicidal ideation (including suicide attempt) is significant factor</description>
          <population>The efficacy analysis population consists of the evaluable cases in accordance with the analysis plan (cases judged to have been evaluated appropriately).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="397"/>
                <count group_id="O2" value="1303"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="319"/>
                    <measurement group_id="O2" value="1136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The factor tested was &quot;suicidal ideation (including suicide attempt)&quot;. The null hypothesis is there is no difference between &quot;with or without suicidal ideation (including suicide attempt)&quot; in the participants of responders.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>not adjusted, p=0.050</p_value_desc>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sertraline</title>
          <description>Participants taking Sertraline according to Japanese Package Insert. All observed or volunteered adverse events and the investigator’s opinion of the causal relationship to the study treatment were reported. Definition of an adverse event (AE) is any adverse change in health or side effect that occurs in participates. Treatment related Adverse Events were evaluated in company with the causal relationship to the investigational product.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA/14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Neuroleptic malignant syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Dissociative disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA/14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="263" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Inappropriate antidiuretic hormone secretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="87" subjects_affected="87" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="21" subjects_affected="21" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Thirst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Hepatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Serotonin syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Neuroleptic malignant syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Dysstasia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Autonomic nervous system imbalance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Psychomotor hyperactivity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Activation syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Dissociative disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Hallucination, visual</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Hallucination, auditory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Intentional self-injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Delusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Withdrawal syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ejaculation delayed</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2157"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2157"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

